Probiotics in the Helicobacter pylori eradication therapy
DOI: 10.32364/2587-6821-2023-7-5-5
M.F. Osipenko1, E.A. Zhuk1, V.P. Drobysheva1, N.V. Litvinova1, M.A. Livzan2, O.V. Gaus2
1Novosibirsk State Medical University, Novosibirsk, Russian Federation
2Omsk State Medical University, Omsk, Russian Federation
Eradication therapy occupies a key place in the treatment of Helicobacter pylori (HP) infections. The presence of HP in the human body can affect the composition of gut microbiota in several ways, including the direct effect of infection or as a consequence of HP eradication regimes. Nowadays, one of the measures to increase the eradication therapy efficacy and reduce the probability of antibiotic-associated disorders is the strategy of gut microbiome modulation. The article discusses the HP effects on the gut microbiota, methods for probiotic correction in conditions of HP infection and eradication therapy. Probiotics have a destructive effect on the biofilm formed by HP, and its destruction can increase the efficacy of antibacterial therapy. The most rational regimen is the administration of probiotics before and during eradication, or at least for two weeks. At the same time, probiotics should include a variety of bacterial strains with proven efficacy and a high safety profile.
Keywords: Helicobacter pylori, microbiota, eradication therapy, probiotics, probiotic correction, antibiotic-associated disorders, inulin.
For citation: Osipenko M.F., Zhuk E.A., Drobysheva V.P., Litvinova N.V., Livzan M.A., Gaus O.V. Probiotics in the Helicobacter pylori eradication therapy. Russian Medical Inquiry. 2023;7(5):274–282 (in Russ.). DOI: 10.32364/2587-6821-2023-7-5-5.
About the authors:
Maria F. Osipenko — Dr. Sc. (Med.), Professor, Head of the Department of Propaedeutics of Internal Medicine, Novosibirsk State Medical University; 52, Krasny ave, Novosibirsk, 630091, Russian Federation; ORCID iD 0000-0002-5156-2842.
Elena A. Zhuk — Dr. Sc. (Med.), Associate Professor of the Department of Propaedeutics of Internal Medicine, Novosibirsk
State Medical University; 52, Krasny ave, Novosibirsk, 630091, Russian Federation; ORCID iD 0000-0002-7416-5428.
Vera P. Drobysheva — Dr. Sc. (Med.), Professor of the Department of Hospital Therapy of the Faculty of Medicine, Novosibirsk State Medical University; 52, Krasny ave, Novosibirsk, 630091, Russian Federation.
Natalia V. Litvinova — C. Sc. (Med.), Associate Professor of the Department of Propaedeutics of Internal Medicine, Novosibirsk State Medical University; 52, Krasny ave, Novosibirsk, 630091, Russian Federation; ORCID iD 0000-0002-9143-6330.
Maria A. Livzan — Dr. Sc. (Med.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Faculty Therapy and Gastroenterology, rector, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0002-6581-7017.
Olga V. Gaus — C. Sc. (Med.), Assistant Professor of the Department of Faculty Therapy and Gastroenterology, Omsk State Medical University; 12, Lenin str., Omsk, 644099, Russian Federation; ORCID iD 0000-0001-9370-4768.
Contact information: Olga V. Gaus, e-mail: gaus_olga@bk.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 12.04.2023.
Revised 26.04.2023.
Accepted 22.05.2023.
References
1. Malfertheiner P., Megraud F., Rokkas T. et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;gutjnl-2022-327745. DOI: 10.1136/gutjnl-2022-327745.
2. Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации «Эндоскопическое общество РЭНДО» по диагностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):70–99. DOI: 10.22416/1382-4376-2021-31-4-70-99. [Ivashkin V.T., Maev I.V., Lapina T.L. et al. linical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70–99 (in Russ.)]. DOI: 10.22416/1382-4376-2021-31-4-70-99.
3. Ливзан М.А., Костенко М.Б. Язвенная болезнь: современные подходы к диагностике и терапии. Лечащий врач. 2010;7:20. [Livzan M.A., Kostenko M.B. Peptic ulcer disease: modern approaches to diagnosis and therapy. Lechashchiy vrach. 2010;7:20 (in Russ.)].
4. Hu Yi., Zhu Y., Lu N.H. Recent progress in Helicobacter pylori treatment. Chinese medical journal. 2020;133(3):335–343. DOI: 10.1097/CM9.0000000000000618.
5. WGO Global Guideline Probiotics and prebiotics. (Electronic resource.) URL: https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english (access date: 20.06.2023).
6. Pereira-Marques J., Ferreira R.M., Machado J.C., Figueiredo C. The influence of the gastric microbiota in gastric cancer development. Best practice & research. Clinical gastroenterology. 2021;50–51:101734. DOI: 10.1016/j.bpg.2021.101734.
7. Vasapolli R., Schütte K., Schulz C. et al. Analysis of Transcriptionally Active Bacteria Throughout the Gastrointestinal Tract of Healthy Individuals. Gastroenterology. 2019;157(4):1081–1092.e3. DOI: 10.1053/j.gastro.2019.05.068.
8. Schulz C., Schütte K., Koch N. et al. The active bacterial assemblages of the upper GI tract in individuals with and without Helicobacter infection. Gut. 2018;67(2):216–225. DOI: 10.1136/gutjnl-2016-312904.
9. Fiorani M., Tohumcu E., Del Vecchio L.E. et al. The Influence of Helicobacter pylori on Human Gastric and Gut Microbiota. Antibiotics (Basel). 2023;12(4):765. DOI: 10.3390/antibiotics12040765.
10. Zhang L., Zhao M., Fu X. Gastric microbiota dysbiosis and Helicobacter pylori infection. Front Microbiol. 2023;14:1153269. DOI: 10.3389/fmicb.2023.1153269.
11. Chen C.C., Liou J.M., Lee Y.C. et al. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021;13(1):1–22. DOI: 10.1080/19490976.2021.1909459.
12. Klymiuk I., Bilgilier C., Stadlmann A. et al. The Human Gastric Microbiome Is Predicated upon Infection with Helicobacter pylori. Front Microbiol. 2017;8:2508. DOI: 10.3389/fmicb.2017.02508.
13. Wang D., Zhang T., Lu Y. et al. Helicobacter pylori infection affects the human gastric microbiome, as revealed by metagenomic sequencing. FEBS Open Bio. 2022;12(6):1188–1196. DOI: 10.1002/2211-5463.13390.
14. Zheng W., Miao J., Luo L. et al. The Effects of Helicobacter pylori Infection on Microbiota Associated with Gastric Mucosa and Immune Factors in Children. Front Immunol. 2021;12:625586. DOI: 10.3389/fimmu.2021.625586.
15. Noto J.M., Peek R.M.Jr. The gastric microbiome, its interaction with Helicobacter pylori, and its potential role in the progression to stomach cancer. PLoS pathogens. 2017;13(10):e1006573. DOI: 10.1371/journal.ppat.1006573.
16. Ливзан М.А., Кононов А.В., Мозговой С.И. Постэрадикационный период хронического гастрита, ассоциированного с инфекцией Helicobacter pylori. Consillium Medicum. 2008;10(8):15–20. [Livzan M.A., Kononov A.V., Mozgovoy S.I. Post-eradiation period of chronic gastritis associated with Helicobacter pylori infection. Consillium Medicum. 2008;10(8):15–20 (in Russ.)].
17. Serrano C., Harris P.R., Smith P.D., Bimczok D. Interactions between H. pylori and the Gastric Microbiome: Impact on Gastric Homeostasis and Disease. Current opinion in physiology. 2021;21:57–64. DOI: 10.1016/j.cophys.2021.04.003.
18. Frost F., Kacprowski T., Rühlemann M. et al. Helicobacter pylori infection associates with fecal microbiota composition and diversity. Scientific reports. 2019;9(1):20100. DOI: 10.1038/s41598-019-56631-4.
19. Guo Y., Zhang Y., Gerhard M. et al. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2020;69(9):1598–1607. DOI: 10.1136/gutjnl-2019-319696.
20. Heimesaat M.M., Fischer A., Plickert R. et al. Helicobacter pylori induced gastric immunopathology is associated with distinct microbiota changes in the large intestines of long-term infected Mongolian gerbils. PLoS One. 2014;9(6):e100362. DOI: 10.1371/journal.pone.0100362.
21. Ramirez J., Guarner F., Bustos Fernandez L. et al. Antibiotics as Major Disruptors of Gut Microbiota. Front Cell Infect Microbiol. 2020;10:572912. DOI: 10.3389/fcimb.2020.572912.
22. Ianiro G., Tilg H., Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;65(11):1906–1915. DOI: 10.1136/gutjnl-2016-312297.
23. Ахмедов В.А. Гаус О.В. Роль кишечной микробиоты в формировании неалкогольной жировой болезни печени. Терапевтический архив. 2019;91(2):143–148. [Akhmedov V.A., Gaus O.V. Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease. Therapeutic Archive. 2019;91(2):143–148 (in Russ.)].
24. Jakobsson H.E., Jernberg C., Andersson A.F. et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836. DOI: 10.1371/journal.pone.0009836.
25. Chen L., Xu W., Lee A. et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomized clinical trial. EBioMedicine. 2018;35:87–96. DOI: 10.1016/j.ebiom.2018.08.028.
26. Weersma R.K., Zhernakova A., Fu J. Interaction between drugs and the gut microbiome. Gut. 2020;69(8):1510–1519. DOI: 10.1136/gutjnl-2019-320204.
27. Imhann F., Bonder M.J., Vich Vila A. et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–748. DOI: 10.1136/gutjnl-2015-310376.
28. Marcusson L.L., Olofsson S.K., Komp Lindgren P. et al. Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother. 2005;55(6):938–943. DOI: 10.1093/jac/dki136.
29. Feng Z.H., Fan L., Yang J. et al. Mutant selection window of clarithromycin for clinical isolates of Helicobacter pylori. BMC Microbiol. 2019;19(1):176. DOI: 10.1186/s12866-019-1558-8.
30. Brooks B.D., Brooks A.E. Therapeutic strategies to combat antibiotic resistance. Adv Drug Deliv Rev. 2014;78:14–27. DOI: 10.1016/j.addr.2014.10.027.
31. Hemaiswarya S., Kruthiventi A.K., Doble M. Synergism between natural products and antibiotics against infectious diseases. Phytomedicine. 2008;15(8):639–652. DOI: 10.1016/j.phymed.2008.06.008.
32. Losurdo G., Cubisino R., Barone M. et al. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World J Gastroenterol. 2018;24(1):139–149. DOI: 10.3748/wjg.v24.i1.139.
33. Viazis N., Argyriou K., Kotzampassi K. et al. A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates. Nutrients. 2022;14(3):632. DOI: 10.3390/nu14030632.
34. Shi X., Zhang J., Mo L. et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180. DOI: 10.1097/MD.0000000000015180.
35. Zagari R.M., Frazzoni L., Marasco G. et al. Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Med. 2021;112(2):281–287. DOI: 10.23736/S0026-4806.20.06810-X.
36. Di Pierro F., Bertuccioli A., Saponara M., Ivaldi L. Impact of a two-bacterial-strain formula, containing Bifidobacterium animalis lactis BB-12 and Enterococcus faecium L3, administered before and after therapy for Helicobacter pylori eradication. Minerva Gastroenterol Dietol. 2020;66(2):117–123. DOI: 10.23736/S1121-421X.19.02651-5.
37. He C., Xie Y., Zhu Y. et al. Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial. Front Immunol. 2022;13:1033063. DOI: 10.3389/fimmu.2022.1033063.
38. Szajewska H., Horvath A., Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015;41(12):1237–1245. DOI: 10.1111/apt.13214.
39. Zhou B.G., Chen L.X., Li B. et al. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019;24(5):e12651. DOI: 10.1111/hel.12651.
40. Han Y.M., Park J.M., Jeong M. et al. Dietary, non-microbial intervention to prevent Helicobacter pylori-associated gastric diseases. Ann Transl Med. 2015;3(9):122. DOI: 10.3978/j.issn.2305-5839.2015.03.50.
41. Byrd J.C., Yunker C.K., Xu Q.S. et al. Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology. 2000;118(6):1072–1079. DOI: 10.1016/s0016-5085(00)70360-x.
42. Suez J., Zmora N., Segal E., Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716–729. DOI: 10.1038/s41591-019-0439-x.
43. Yang Y.J., Chung C.C., Yang H.B. et al. Lactobacillus acidophilus ameliorates H. pylori-induced gastric inflammation by inactivating the Smad7 and NFΚB pathways. BMC Microbiol. 2012;12:38. DOI: 10.1186/1471-2180-12-38.
44. Zheng P.X., Fang H.Y., Yang H.B. et al. Lactobacillus pentosus strain LPS16 produces lactic acid, inhibiting multidrug-resistant Helicobacter pylori. J Microbiol Immunol Infect. 201;49(2):168–174. DOI: 10.1016/j.jmii.2014.04.014.
45. Batdorj B., Trinetta V., Dalgalarrondo M. et al. Isolation, taxonomic identification and hydrogen peroxide production by Lactobacillys delbrueckii subsp lactis T31, isolated from Mongolian yoghurt: Inhibitory activity on food-borne pathogens fool-borne pathogens. J Appl Microbiol. 2007;103(3):584–593. DOI: 10.1111/j.1365-2672.2007.03279.
46. Kim T.S., Hur J.W., Yu M.A. et al. Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria. J Food Prot. 2003;66(1):3–12. DOI: 10.4315/0362-028x-66.1.3.
47. Boyanova L., Gergova G., Markovska R. et al. Bacteriocin-like inhibitory activities of seven Lactobacillus delbrueckii subsp. bulgaricus strains against antibiotic susceptible and resistant Helicobacter pylori strains. Lett Appl Microbiol. 2017;65(6):469–474. DOI: 10.1111/lam.12807.
48. Lesbros-Pantoflickova D., Corthésy-Theulaz I., Blum A.L. Helicobacter pylori and probiotics. J Nutr. 2007;137(3 Suppl 2):812S–818S. DOI: 10.1093/jn/137.3.812S.
49. Mukai T., Asasaka T., Sato E. et al. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 2002;32(2):105–110. DOI: 10.1111/j.1574-695X.2002.tb00541.x.
50. De Klerk N., Maudsdotter L., Gebreegziabher H. et al. Lactobacilli reduce Helicobacter pylori attachment to host gastric epithelial cells by inhibiting adhesion gene expression. Infect Immun. 2016;84(5):1526–1535. DOI: 10.1128/IAI.00163-16.
51. De La Fuente-Núñez C., Reffuveille F., Fernández L., Hancock R.E. Bacterial biofilm development as a multicellular adaptation: Antibiotic resistance and new therapeutic strategies. Curr Opin Microbiol. 2013;16(5):580–589. DOI: 10.1016/j.mib.2013.06.013.
52. Rizzato C., Torres J., Kasamatsu E. et al. Potential Role of Biofilm Formation in the Development of Digestive Tract Cancer With Special Reference to Helicobacter pylori Infection. Front Microbiol. 2019;10:846. DOI: 10.3389/fmicb.2019.00846.
53. Ge X., Cai Y., Chen Z. et al. Bifunctional Enzyme SpoT Is Involved in Biofilm Formation of Helicobacter pylori with Multidrug Resistance by Upregulating Efflux Pump Hp1174 (gluP). Antimicrob Agents Chemother. 2018;62(11):e00957–e01018. DOI: 10.1128/AAC.00957-18.
54. Hathroubi S., Servetas S.L., Windham I. et al. Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis. Microbiol Mol Biol Rev. 2018;82(2):e00001–e00018. DOI: 10.1128/MMBR.00001-18.
55. Song H., Zhang J., Qu J. et al. Lactobacillus rhamnosus GG microcapsules inhibit Escherichia coli biofilm formation in coculture. Biotechnol Lett. 2019;41(8-9):1007–1014. DOI: 10.1007/s10529-019-02694-2.
56. Merino L., Trejo F.M., De Antoni G., Golowczyc M.A. Lactobacillus strains inhibit biofilm formation of Salmonella sp. isolates from poultry. Food Res Int. 2019;123:258–265. DOI: 10.1016/j.foodres.2019.04.067.
57. Cammarota G., Branca G., Ardito F. et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol. 2010;8(9):817–820.e3. DOI: 10.1016/j.cgh.2010.05.006.
58. Jung S., Park O.J., Kim A.R. et al. Lipoteichoic acids of lactobacilli inhibit Enterococcus faecalis biofilm formation and disrupt the preformed biofilm. J Microbiol. 2019;57(4):310–315. DOI: 10.1007/s12275-019-8538-4.
59. Ливзан М.А., Гаус О.В., Мозговой С.И. Хронический атрофический гастрит: тактика курации пациента. РМЖ. Медицинское обозрение. 2021;5(6):427–432. DOI: 10.32364/2587-6821-2021-5-6-427-432. [Livzan M.A., Gaus O.V., Mozgovoi S.I. Chronic atrophic gastritis: patient management. Russian Medical Inquiry. 2021;5(6):427–432 (in Russ.)]. DOI: 10.32364/2587-6821-2021-5-6-427-432.
60. He C., Peng C., Xu X. et al. Probiotics mitigate Helicobacter pylori-induced gastric inflammation and premalignant lesions in INS-GAS mice with the modulation of gastrointestinal microbiota. Helicobacter. 2022;27(4):e12898. DOI: 10.1111/hel.12898.
61. Marinelli P., Scalese G., Covelli A. et al. Lactobacillus rhamnosus GG supplementation on eradication rate and dyspepsia in Helicobacter pylori infection treated with three-in-one bismuth quadruple therapy. Front Microbiol. 2022;13:932331. DOI: 10.3389/fmicb.2022.932331.
62. Cai X., Li X., Jin Y. et al. Vitamins and Helicobacter pylori: An Updated Comprehensive Meta-Analysis and Systematic Review. Front Nutr. 2022;8:781333. DOI: 10.3389/fnut.2021.781333.
63. Lorca G.L., Wadström T., Font de Valdez G., Ljungh Å. Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol. 2001;42(1):39–44. DOI: 10.1007/s002840010175.
64. Foligne B., Nutten S., Grangette C. et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol. 2007;13(2):236–243. DOI: 10.3748/wjg.v13.i2.236.
65. Engelbrektson A., Korzenik J.R., Pittler A. et al. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol. 2009;58(Pt 5):663–670. DOI: 10.1099/jmm.0.47615-0.
66. Turner R.B., Woodfolk J.A., Borish L. et al. Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection — a randomised controlled trial. Benef Microbes. 2017;8(2):207–215. DOI: 10.3920/BM2016.0160.
67. Foligne B., Zoumpopoulou G., Dewulf J. et al. A key role of dendritic cells in probiotic functionality. PLoS One. 2007;2(3):e313. DOI: 10.1371/journal.pone.0000313.
68. Ардатская М.Д., Анучкин А.А., Буторова Л.И. и др. Патогенетические аспекты развития и лечения антибиотикоассоциированной диареи: выбор синбиотики с признаками доказательной медицины. Медицинский Совет. 2023;6:113–125. DOI: 10.21518/ms2023-026. [Ardatskaya M.D., Anuchkin A.A., Butorova L.I. et al. Pathogenetic aspects of the development and treatment of antibiotic-associated diarrhea: the choice of a synbiotic from the standpoint of evidence-based medicine. Meditsinskiy sovet. 2023;6:113–125 (in Russ.)]. DOI: 10.21518/ms2023-026.
2. Ивашкин В.Т., Маев И.В., Лапина Т.Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и ассоциации «Эндоскопическое общество РЭНДО» по диагностике и лечению гастрита, дуоденита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(4):70–99. DOI: 10.22416/1382-4376-2021-31-4-70-99. [Ivashkin V.T., Maev I.V., Lapina T.L. et al. linical Recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70–99 (in Russ.)]. DOI: 10.22416/1382-4376-2021-31-4-70-99.
3. Ливзан М.А., Костенко М.Б. Язвенная болезнь: современные подходы к диагностике и терапии. Лечащий врач. 2010;7:20. [Livzan M.A., Kostenko M.B. Peptic ulcer disease: modern approaches to diagnosis and therapy. Lechashchiy vrach. 2010;7:20 (in Russ.)].
4. Hu Yi., Zhu Y., Lu N.H. Recent progress in Helicobacter pylori treatment. Chinese medical journal. 2020;133(3):335–343. DOI: 10.1097/CM9.0000000000000618.
5. WGO Global Guideline Probiotics and prebiotics. (Electronic resource.) URL: https://www.worldgastroenterology.org/guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english (access date: 20.06.2023).
6. Pereira-Marques J., Ferreira R.M., Machado J.C., Figueiredo C. The influence of the gastric microbiota in gastric cancer development. Best practice & research. Clinical gastroenterology. 2021;50–51:101734. DOI: 10.1016/j.bpg.2021.101734.
7. Vasapolli R., Schütte K., Schulz C. et al. Analysis of Transcriptionally Active Bacteria Throughout the Gastrointestinal Tract of Healthy Individuals. Gastroenterology. 2019;157(4):1081–1092.e3. DOI: 10.1053/j.gastro.2019.05.068.
8. Schulz C., Schütte K., Koch N. et al. The active bacterial assemblages of the upper GI tract in individuals with and without Helicobacter infection. Gut. 2018;67(2):216–225. DOI: 10.1136/gutjnl-2016-312904.
9. Fiorani M., Tohumcu E., Del Vecchio L.E. et al. The Influence of Helicobacter pylori on Human Gastric and Gut Microbiota. Antibiotics (Basel). 2023;12(4):765. DOI: 10.3390/antibiotics12040765.
10. Zhang L., Zhao M., Fu X. Gastric microbiota dysbiosis and Helicobacter pylori infection. Front Microbiol. 2023;14:1153269. DOI: 10.3389/fmicb.2023.1153269.
11. Chen C.C., Liou J.M., Lee Y.C. et al. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021;13(1):1–22. DOI: 10.1080/19490976.2021.1909459.
12. Klymiuk I., Bilgilier C., Stadlmann A. et al. The Human Gastric Microbiome Is Predicated upon Infection with Helicobacter pylori. Front Microbiol. 2017;8:2508. DOI: 10.3389/fmicb.2017.02508.
13. Wang D., Zhang T., Lu Y. et al. Helicobacter pylori infection affects the human gastric microbiome, as revealed by metagenomic sequencing. FEBS Open Bio. 2022;12(6):1188–1196. DOI: 10.1002/2211-5463.13390.
14. Zheng W., Miao J., Luo L. et al. The Effects of Helicobacter pylori Infection on Microbiota Associated with Gastric Mucosa and Immune Factors in Children. Front Immunol. 2021;12:625586. DOI: 10.3389/fimmu.2021.625586.
15. Noto J.M., Peek R.M.Jr. The gastric microbiome, its interaction with Helicobacter pylori, and its potential role in the progression to stomach cancer. PLoS pathogens. 2017;13(10):e1006573. DOI: 10.1371/journal.ppat.1006573.
16. Ливзан М.А., Кононов А.В., Мозговой С.И. Постэрадикационный период хронического гастрита, ассоциированного с инфекцией Helicobacter pylori. Consillium Medicum. 2008;10(8):15–20. [Livzan M.A., Kononov A.V., Mozgovoy S.I. Post-eradiation period of chronic gastritis associated with Helicobacter pylori infection. Consillium Medicum. 2008;10(8):15–20 (in Russ.)].
17. Serrano C., Harris P.R., Smith P.D., Bimczok D. Interactions between H. pylori and the Gastric Microbiome: Impact on Gastric Homeostasis and Disease. Current opinion in physiology. 2021;21:57–64. DOI: 10.1016/j.cophys.2021.04.003.
18. Frost F., Kacprowski T., Rühlemann M. et al. Helicobacter pylori infection associates with fecal microbiota composition and diversity. Scientific reports. 2019;9(1):20100. DOI: 10.1038/s41598-019-56631-4.
19. Guo Y., Zhang Y., Gerhard M. et al. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2020;69(9):1598–1607. DOI: 10.1136/gutjnl-2019-319696.
20. Heimesaat M.M., Fischer A., Plickert R. et al. Helicobacter pylori induced gastric immunopathology is associated with distinct microbiota changes in the large intestines of long-term infected Mongolian gerbils. PLoS One. 2014;9(6):e100362. DOI: 10.1371/journal.pone.0100362.
21. Ramirez J., Guarner F., Bustos Fernandez L. et al. Antibiotics as Major Disruptors of Gut Microbiota. Front Cell Infect Microbiol. 2020;10:572912. DOI: 10.3389/fcimb.2020.572912.
22. Ianiro G., Tilg H., Gasbarrini A. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut. 2016;65(11):1906–1915. DOI: 10.1136/gutjnl-2016-312297.
23. Ахмедов В.А. Гаус О.В. Роль кишечной микробиоты в формировании неалкогольной жировой болезни печени. Терапевтический архив. 2019;91(2):143–148. [Akhmedov V.A., Gaus O.V. Role of intestinal microbiota in the formation of non-alcoholic fatty liver disease. Therapeutic Archive. 2019;91(2):143–148 (in Russ.)].
24. Jakobsson H.E., Jernberg C., Andersson A.F. et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836. DOI: 10.1371/journal.pone.0009836.
25. Chen L., Xu W., Lee A. et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomized clinical trial. EBioMedicine. 2018;35:87–96. DOI: 10.1016/j.ebiom.2018.08.028.
26. Weersma R.K., Zhernakova A., Fu J. Interaction between drugs and the gut microbiome. Gut. 2020;69(8):1510–1519. DOI: 10.1136/gutjnl-2019-320204.
27. Imhann F., Bonder M.J., Vich Vila A. et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–748. DOI: 10.1136/gutjnl-2015-310376.
28. Marcusson L.L., Olofsson S.K., Komp Lindgren P. et al. Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother. 2005;55(6):938–943. DOI: 10.1093/jac/dki136.
29. Feng Z.H., Fan L., Yang J. et al. Mutant selection window of clarithromycin for clinical isolates of Helicobacter pylori. BMC Microbiol. 2019;19(1):176. DOI: 10.1186/s12866-019-1558-8.
30. Brooks B.D., Brooks A.E. Therapeutic strategies to combat antibiotic resistance. Adv Drug Deliv Rev. 2014;78:14–27. DOI: 10.1016/j.addr.2014.10.027.
31. Hemaiswarya S., Kruthiventi A.K., Doble M. Synergism between natural products and antibiotics against infectious diseases. Phytomedicine. 2008;15(8):639–652. DOI: 10.1016/j.phymed.2008.06.008.
32. Losurdo G., Cubisino R., Barone M. et al. Probiotic monotherapy and Helicobacter pylori eradication: A systematic review with pooled-data analysis. World J Gastroenterol. 2018;24(1):139–149. DOI: 10.3748/wjg.v24.i1.139.
33. Viazis N., Argyriou K., Kotzampassi K. et al. A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates. Nutrients. 2022;14(3):632. DOI: 10.3390/nu14030632.
34. Shi X., Zhang J., Mo L. et al. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180. DOI: 10.1097/MD.0000000000015180.
35. Zagari R.M., Frazzoni L., Marasco G. et al. Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Med. 2021;112(2):281–287. DOI: 10.23736/S0026-4806.20.06810-X.
36. Di Pierro F., Bertuccioli A., Saponara M., Ivaldi L. Impact of a two-bacterial-strain formula, containing Bifidobacterium animalis lactis BB-12 and Enterococcus faecium L3, administered before and after therapy for Helicobacter pylori eradication. Minerva Gastroenterol Dietol. 2020;66(2):117–123. DOI: 10.23736/S1121-421X.19.02651-5.
37. He C., Xie Y., Zhu Y. et al. Probiotics modulate gastrointestinal microbiota after Helicobacter pylori eradication: A multicenter randomized double-blind placebo-controlled trial. Front Immunol. 2022;13:1033063. DOI: 10.3389/fimmu.2022.1033063.
38. Szajewska H., Horvath A., Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther. 2015;41(12):1237–1245. DOI: 10.1111/apt.13214.
39. Zhou B.G., Chen L.X., Li B. et al. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019;24(5):e12651. DOI: 10.1111/hel.12651.
40. Han Y.M., Park J.M., Jeong M. et al. Dietary, non-microbial intervention to prevent Helicobacter pylori-associated gastric diseases. Ann Transl Med. 2015;3(9):122. DOI: 10.3978/j.issn.2305-5839.2015.03.50.
41. Byrd J.C., Yunker C.K., Xu Q.S. et al. Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology. 2000;118(6):1072–1079. DOI: 10.1016/s0016-5085(00)70360-x.
42. Suez J., Zmora N., Segal E., Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716–729. DOI: 10.1038/s41591-019-0439-x.
43. Yang Y.J., Chung C.C., Yang H.B. et al. Lactobacillus acidophilus ameliorates H. pylori-induced gastric inflammation by inactivating the Smad7 and NFΚB pathways. BMC Microbiol. 2012;12:38. DOI: 10.1186/1471-2180-12-38.
44. Zheng P.X., Fang H.Y., Yang H.B. et al. Lactobacillus pentosus strain LPS16 produces lactic acid, inhibiting multidrug-resistant Helicobacter pylori. J Microbiol Immunol Infect. 201;49(2):168–174. DOI: 10.1016/j.jmii.2014.04.014.
45. Batdorj B., Trinetta V., Dalgalarrondo M. et al. Isolation, taxonomic identification and hydrogen peroxide production by Lactobacillys delbrueckii subsp lactis T31, isolated from Mongolian yoghurt: Inhibitory activity on food-borne pathogens fool-borne pathogens. J Appl Microbiol. 2007;103(3):584–593. DOI: 10.1111/j.1365-2672.2007.03279.
46. Kim T.S., Hur J.W., Yu M.A. et al. Antagonism of Helicobacter pylori by bacteriocins of lactic acid bacteria. J Food Prot. 2003;66(1):3–12. DOI: 10.4315/0362-028x-66.1.3.
47. Boyanova L., Gergova G., Markovska R. et al. Bacteriocin-like inhibitory activities of seven Lactobacillus delbrueckii subsp. bulgaricus strains against antibiotic susceptible and resistant Helicobacter pylori strains. Lett Appl Microbiol. 2017;65(6):469–474. DOI: 10.1111/lam.12807.
48. Lesbros-Pantoflickova D., Corthésy-Theulaz I., Blum A.L. Helicobacter pylori and probiotics. J Nutr. 2007;137(3 Suppl 2):812S–818S. DOI: 10.1093/jn/137.3.812S.
49. Mukai T., Asasaka T., Sato E. et al. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 2002;32(2):105–110. DOI: 10.1111/j.1574-695X.2002.tb00541.x.
50. De Klerk N., Maudsdotter L., Gebreegziabher H. et al. Lactobacilli reduce Helicobacter pylori attachment to host gastric epithelial cells by inhibiting adhesion gene expression. Infect Immun. 2016;84(5):1526–1535. DOI: 10.1128/IAI.00163-16.
51. De La Fuente-Núñez C., Reffuveille F., Fernández L., Hancock R.E. Bacterial biofilm development as a multicellular adaptation: Antibiotic resistance and new therapeutic strategies. Curr Opin Microbiol. 2013;16(5):580–589. DOI: 10.1016/j.mib.2013.06.013.
52. Rizzato C., Torres J., Kasamatsu E. et al. Potential Role of Biofilm Formation in the Development of Digestive Tract Cancer With Special Reference to Helicobacter pylori Infection. Front Microbiol. 2019;10:846. DOI: 10.3389/fmicb.2019.00846.
53. Ge X., Cai Y., Chen Z. et al. Bifunctional Enzyme SpoT Is Involved in Biofilm Formation of Helicobacter pylori with Multidrug Resistance by Upregulating Efflux Pump Hp1174 (gluP). Antimicrob Agents Chemother. 2018;62(11):e00957–e01018. DOI: 10.1128/AAC.00957-18.
54. Hathroubi S., Servetas S.L., Windham I. et al. Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis. Microbiol Mol Biol Rev. 2018;82(2):e00001–e00018. DOI: 10.1128/MMBR.00001-18.
55. Song H., Zhang J., Qu J. et al. Lactobacillus rhamnosus GG microcapsules inhibit Escherichia coli biofilm formation in coculture. Biotechnol Lett. 2019;41(8-9):1007–1014. DOI: 10.1007/s10529-019-02694-2.
56. Merino L., Trejo F.M., De Antoni G., Golowczyc M.A. Lactobacillus strains inhibit biofilm formation of Salmonella sp. isolates from poultry. Food Res Int. 2019;123:258–265. DOI: 10.1016/j.foodres.2019.04.067.
57. Cammarota G., Branca G., Ardito F. et al. Biofilm demolition and antibiotic treatment to eradicate resistant Helicobacter pylori: a clinical trial. Clin Gastroenterol Hepatol. 2010;8(9):817–820.e3. DOI: 10.1016/j.cgh.2010.05.006.
58. Jung S., Park O.J., Kim A.R. et al. Lipoteichoic acids of lactobacilli inhibit Enterococcus faecalis biofilm formation and disrupt the preformed biofilm. J Microbiol. 2019;57(4):310–315. DOI: 10.1007/s12275-019-8538-4.
59. Ливзан М.А., Гаус О.В., Мозговой С.И. Хронический атрофический гастрит: тактика курации пациента. РМЖ. Медицинское обозрение. 2021;5(6):427–432. DOI: 10.32364/2587-6821-2021-5-6-427-432. [Livzan M.A., Gaus O.V., Mozgovoi S.I. Chronic atrophic gastritis: patient management. Russian Medical Inquiry. 2021;5(6):427–432 (in Russ.)]. DOI: 10.32364/2587-6821-2021-5-6-427-432.
60. He C., Peng C., Xu X. et al. Probiotics mitigate Helicobacter pylori-induced gastric inflammation and premalignant lesions in INS-GAS mice with the modulation of gastrointestinal microbiota. Helicobacter. 2022;27(4):e12898. DOI: 10.1111/hel.12898.
61. Marinelli P., Scalese G., Covelli A. et al. Lactobacillus rhamnosus GG supplementation on eradication rate and dyspepsia in Helicobacter pylori infection treated with three-in-one bismuth quadruple therapy. Front Microbiol. 2022;13:932331. DOI: 10.3389/fmicb.2022.932331.
62. Cai X., Li X., Jin Y. et al. Vitamins and Helicobacter pylori: An Updated Comprehensive Meta-Analysis and Systematic Review. Front Nutr. 2022;8:781333. DOI: 10.3389/fnut.2021.781333.
63. Lorca G.L., Wadström T., Font de Valdez G., Ljungh Å. Lactobacillus acidophilus autolysins inhibit Helicobacter pylori in vitro. Curr Microbiol. 2001;42(1):39–44. DOI: 10.1007/s002840010175.
64. Foligne B., Nutten S., Grangette C. et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol. 2007;13(2):236–243. DOI: 10.3748/wjg.v13.i2.236.
65. Engelbrektson A., Korzenik J.R., Pittler A. et al. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol. 2009;58(Pt 5):663–670. DOI: 10.1099/jmm.0.47615-0.
66. Turner R.B., Woodfolk J.A., Borish L. et al. Effect of probiotic on innate inflammatory response and viral shedding in experimental rhinovirus infection — a randomised controlled trial. Benef Microbes. 2017;8(2):207–215. DOI: 10.3920/BM2016.0160.
67. Foligne B., Zoumpopoulou G., Dewulf J. et al. A key role of dendritic cells in probiotic functionality. PLoS One. 2007;2(3):e313. DOI: 10.1371/journal.pone.0000313.
68. Ардатская М.Д., Анучкин А.А., Буторова Л.И. и др. Патогенетические аспекты развития и лечения антибиотикоассоциированной диареи: выбор синбиотики с признаками доказательной медицины. Медицинский Совет. 2023;6:113–125. DOI: 10.21518/ms2023-026. [Ardatskaya M.D., Anuchkin A.A., Butorova L.I. et al. Pathogenetic aspects of the development and treatment of antibiotic-associated diarrhea: the choice of a synbiotic from the standpoint of evidence-based medicine. Meditsinskiy sovet. 2023;6:113–125 (in Russ.)]. DOI: 10.21518/ms2023-026.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
